Relation of homocysteine and C-reactive protein to urinary albumin loss

American Journal of Cardiology

Volumn 93, Issue 7, 2004, Pages 926-928

  Seshadri, Niranjan ^b   Messerli, Adrian W ^b   Acharya, Naveen ^b   Pearce, Gregory L ^b   Jacobsen, Donald W ^b   Pohl, Marc A ^b   Robinson, Killian ^b   Sprecher, Dennis L ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; C REACTIVE PROTEIN; HOMOCYSTEINE;

ADULT; AGED; ARTICLE; CIGARETTE SMOKING; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; FEMALE; FLUORESCENCE POLARIZATION IMMUNOASSAY; HUMAN; MAJOR CLINICAL STUDY; MALE; NEPHELOMETRY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; PROTEIN URINE LEVEL; SYSTOLIC HYPERTENSION;

ADULT; AGED; ALBUMINURIA; C-REACTIVE PROTEIN; CREATININE; ENDOTHELIUM, VASCULAR; FEMALE; HOMOCYSTEINE; HUMANS; MALE; MIDDLE AGED; VASCULAR DISEASES;

EID: 1842581571     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2003.12.038     Document Type: Article

References (19)

1. Seshadri N., Robinson K. Homocysteine, B vitamins, and coronary artery disease. Med Clin North Am. 84:2000;215-237.
2. Venugopal S.K., Devaraj S., Yuhanna I., Shaul P., Jialal I. Demonstration that C-reactive protein decreases eNOS expression and bioactivity in human aortic endothelial cells. Circulation. 106:2002;1439-1441.
3. Jager A., Kostense P.J., Nijpels G., Dekker J.M., Heine R.J., Bouter L.M., Donker A.J., Stehouwer C.D. Serum homocysteine levels are associated with the development of (micro)albuminuria the Hoorn study. Arterioscler Thromb Vasc Biol. 21:2001;74-81.
4. Pannacciulli N., Cantatore F.P., Minenna A., Bellacicco M., Giorgino R., De Pergola G. Urinary albumin excretion is independently associated with C-reactive protein levels in overweight and obese nondiabetic premenopausal women. J Intern Med. 250:2001;502-507.
5. Jager A., Van Hinsbergh V.W., Kostense P.J., Emeis J.J., Nijpels G., Dekker J.M., Heine R.J., Bouter L.M., Stehouwer C.D. C-reactive protein and soluble vascular cell adhesion molecule-1 are associated with elevated urinary albumin excretion but do not expain its link with cardiovascular risk. Arterioscler Thromb Vasc Biol. 22:2002;593-598.
6. Froklis J., Sprecher D.L., Foody J.M., Pearce G.L. Improving risk factor control in heart disease the effectiveness of a multidisciplinary preventive cardiology program. Prev Med Manag Care. 1:2000;77-88.
7. Ridker P.M. High-sensitivity C-reactive protein potential adjunct for global risk assessment in the primary prevention of cardiovascular disease. Circulation. 103:2001;1813-1818.
8. Gerstein H.C., Mann J.F., Yi Q., Zinman B., Dinneen S.F., Hoogwerf B., Halle J.P., Young J., Rashkow A., Joyce C., et al. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA. 286:2001;421-426.
9. Rifai N., Ridker P.M. High-sensitivity C-reactive protein a novel and promising marker of coronary heart disease. Clin Chem. 47:2001;403-411.
10. Cleland S.J., Sattar N., Petrie J.R., Forouhi N.G., Elliott H.L., Connell J.M. Endothelial dysfunction as a possible link between C-reactive protein levels and cardiovascular disease. Clin Sci (Lond). 98:2000;531-535.
11. Castell J.V., Gomez-Lechon M.J., David M., Andus T., Geiger T., Trullenque R., Fabra R., Heinrich P.C. Interleukin-6 is the major regulator of acute phase protein synthesis in adult human hepatocytes. FEBS Lett. 242:1989;237-239.
12. Poddar R., Sivasubramanian N., DiBello P.M., Robinson K., Jacobsen D.W. Homocysteine induces expression and secretion of monocyte chemoattractant protein-1 and interleukin-8 in human aortic endothelial cells implications for vascular disease. Circulation. 103:2001;2717-2723.
13. Becker A., Van Hinsbergh V.W., Kostense P.J., Jager A., Dekker J.M., Nijpels G., Heine R.J., Bouter L.M., Stehouwer C.D. Serum homocysteine is weakly associated with von Willebrand factor and soluble vascular cell adhesion molecule 1, but not with C-reactive protein in type 2 diabetic and non-diabetic subjects - the Hoorn Study. Eur J Clin Invest. 30:2000;763-770.
14. Loscalzo J. The oxidant stress of hyperhomocyst(e)inemia. J Clin Invest. 98:1996;5-7.
15. Hajjar K.A., Jacovina A.T. Modulation of annexin II by homocysteine implications for atherothrombosis. J Investig Med. 46:1998;364-369.
16. Sengupta S., Wehbe C., Majors A.K., Ketterer M.E., DiBello P.M., Jacobsen D.W. Relative roles of albumin and ceruloplasmin in the formation of homocystine, homocysteine-cysteine-mixed disulfide, and cystine in circulation. J Biol Chem. 276:2001;46896-46904.
17. Majors A.K., Sengupta S., Willard B., Kinter M.T., Pyeritz R.E., Jacobsen D.W. Homocysteine binds to human plasma fibronectin and inhibits its interaction with fibrin. Arterioscler Thromb Vasc Biol. 22:2002;1354-1359.
18. Werstuck G.H., Lentz S.R., Dayal S., Hossain G.S., Sood S.K., Shi Y.Y., Zhou J., Maeda N., Krisans S.K., Malinow M.R., Austin R.C. Homocysteine-induced endoplasmic reticulum stress causes dysregulation of the cholesterol and triglyceride biosynthetic pathways. J Clin Invest. 107:2001;1263-1273.
19. Upchurch G.R. Jr, Welch G.N., Fabian A.J., Freedman J.E., Johnson J.L., Keaney J.F. Jr, Loscalzo J. Homocyst(e)ine decreases bioavailable nitric oxide by a mechanism involving glutathione peroxidase. J Biol Chem. 272:1997;17012-17017.